|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
1.83/2.17
|
Enterprise Value
1.27B
|
Balance Sheet |
Book Value Per Share
9.66
|
Cash Flow |
Cash Flow Yield
0.12
|
Income Statement |
Total Revenue
492.05M
|
Operating Revenue Per Share
6.54
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/01/21 05:24 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medicalaesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States. |